Indeed, each of these checkpoint inhibitors has been shown to have both overlapping and unique effects on tumor-specific T cells and facilitate the conversion of a TME from “cold” to “hot.” Substantial data already exist to indicate that certain combination therapies may overcome the limitations of CTLA-4 blockade and PD-1/PD-L1 blockade monotherapies. Here, PDCD1 is linked to neoplasm.